Neffy Spray
Product Images NDC 85766-130

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Neffy (NDC 85766-130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sportpharm Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Label 1mg)

Packaging label for neffy nasal spray containing epinephrine 1 mg per 100 µL strength. The label shows a quantity of 2 single-dose nasal spray devices, manufactured by ARS Pharmaceuticals Operations, with associated product identification codes including NDC 85766-129-02. The labeler is Sportpharm LLC.*

FDA Label Image

2 (Label 2mg)

The label for neffy (epinephrine nasal spray) 2 mg, relabeled for Sportpharm LLC. It includes NDC 85766-130-02 and shows a quantity of 2 spray devices. The manufacturer is listed as ARS Pharmaceuticals Operations, Inc. The label also contains batch, lot, and expiration date placeholders, and storage instructions to keep the product at 20-25°C and out of reach of children.*

FDA Label Image

Figure 1 (Neffy 01)

An instructional illustration showing the administration of two nasal spray doses of neffy (epinephrine). The first image depicts a person spraying the nasal spray into one nostril. The second image shows a close-up of the same nostril receiving the second dose with directional indicators for spray placement.*

FDA Label Image

Chemical Structure (Neffy 02)

Chemical structure of epinephrine, showing the molecular arrangement of atoms including hydroxyl groups and an amine group, consistent with the active ingredient in neffy nasal spray.*

FDA Label Image

Figure 2 (Neffy 03)

A line graph comparing median pulse rate changes from baseline over 60 minutes for neffy 2 mg, epinephrine 0.3 mg administered by needle-syringe, and epinephrine 0.3 mg administered by auto-injector. The y-axis shows pulse rate change in beats per minute, and the x-axis shows time in minutes.*

FDA Label Image

Figure 2 (Neffy 04)

A line graph showing the median systolic blood pressure (SBP) change from baseline (mmHg) over 60 minutes. It compares three treatments: neffy 2 mg nasal spray, epinephrine 0.3 mg via needle-syringe, and epinephrine 0.3 mg via auto-injector, with distinct lines representing each.*

FDA Label Image

Figure 3 (Neffy 05)

Two line graphs showing median pulse rate change (bpm) and median systolic blood pressure (SBP) change (mm Hg) over 60 minutes. The graphs compare effects of neffy 2 mg administered twice right/left without NAC, neffy 2 mg twice right/right with NAC, and epinephrine 0.3 mg twice right/left with NAC.*

FDA Label Image

Figure 4 (Neffy 06)

A pharmacokinetic graph showing epinephrine plasma concentration (pg/mL) on the y-axis over time (minutes) on the x-axis up to 60 minutes. It compares neffy 2 mg nasal spray with 0.3 mg epinephrine given by needle-syringe and auto-injector, illustrating differences in concentration profiles and peak times.*

FDA Label Image

Figure 5 (Neffy 07)

This image contains two line graphs comparing epinephrine plasma concentrations over time in minutes. Graph (a) shows epinephrine plasma concentration (pg/mL) for neffy 2 mg with and without NAC versus epinephrine 0.3 mg and 0.5 mg administered via needle-syringe. Graph (b) displays geometric mean concentration (pg/mL) for neffy 2 mg administered twice right/left nostrils with and without NAC, compared to epinephrine 0.3 mg given twice right/left nostrils with NAC. Both graphs illustrate concentration changes up to 60 minutes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.